Introduction
Protein kinase C (PKC) is a family of phospholipiddependent serine-threonine protein kinases consisting of 12 members that play important roles in signal transduction pathways that regulate growth and dierentiation, in a variety of cell types (for review see Borner and Fabbro, 1992; Goodnight et al., 1994; Jaken, 1996) . Individual PKC isoforms show dierent substrate speci®cities, sub-cellular localization, cofactor requirements, and sensitivity to agonist induced down-regulation Jaken, 1996) . The phenotypic eects of ectopic overexpression of speci®c isoforms of PKC in various cell types are strongly dependent on both the cell type and isoform examined (Blumberg et al., 1994; Borner et al., 1991; Cacace et al., 1993; Housey et al., 1988) . Several studies implicate an important role for PKC in human breast cancers Gordge et al., 1996; Kiley et al., 1996; O'Brian et al., 1989) . Treatment of normal mammary epithelial cells with phorbol esters stimulated proliferation, whereas phorbol esters inhibited the growth of breast cancer cell lines (Kiley et al., 1996) . These results implicate alterations in PKC function in the progression of mammary cells to a transformed state. Increased Ca 2+ -dependent PKC activity, and PKCa protein levels, were found when primary breast tumors were compared to normal adjacent tissue (Gordge et al., 1996; O'Brian et al., 1989) . Amongst breast cancers an increase in total PKC activity has been associated with the more biologically aggressive estrogen-receptor negative and EGF-receptor positive subset (Borner et al., 1987; Fabbro et al., 1986 Fabbro et al., , 1992 . Furthermore, Tamoxifen, an eective chemotherapeutic agent for breast cancer can bind to and inhibit PKC, in addition to its direct eects on the estrogen receptor (O'Brian et al., 1985) . However, the roles of individual PKC isoforms in the growth, cell cycle control and dierentiation of the normal mammary epithelium and in breast cancer are not well de®ned.
Experiments in which PKCa was ectopically overexpressed in the human breast cancer MCF-7 cell line have produced contradictory results. One study found that MCF7 cells that overexpressed PKCa (or PKCb 1 ) showed decreased tumorigenicity in nude mice, although their in vitro proliferation rate was similar to that of the vector control cells (Manni et al., 1996) . However, a second study found that MCF-7 cells that overexpressed PKCa displayed an enhanced proliferative rate, anchorage-independent growth and increased tumorigenicity in nude mice (Ways et al., 1995) . This confusion contributes to the need to clarify the function of individual isoforms of PKC in normal mammary epithelia and breast cancers.
In the present study we utilized the nontransformed mouse mammary epithelial cell line, HC11, which expresses PKCa, d, e, and z (Ball et al., 1988; Marte et al., 1994) , to obtain insights into the roles of speci®c isoforms of PKC on growth and cell cycle control in normal mammary epithelial cells.
Results

Eects of TPA on growth and expression of endogenous isoforms of PKC in the parental HC11 cells
Treatment of exponentially dividing cultures of the parental HC11 cells with 100 ng/ml TPA caused transient growth inhibition, for about 24 h, after which the doubling time of the cells recovered (data not shown). Therefore, we analysed the cell cycle distribution, by¯ow cytometry, of exponentially growing HC11 cells, following treatment with TPA (100 ng/ml) for various times (Table 1) . Cultures treated with TPA for 6 h had a signi®cantly higher per cent of cells in the G0/G1 phase of the cell cycle, and a corresponding decrease in the per cent in S phase, when compared to the untreated cells (Table 1) . This eect was transient since by 24 h after TPA addition, the cell cycle distribution had largely returned to that of the untreated cells (Table 1 ). In fact, there was an overshoot in the recovery of the S phase fraction (Table 1) . This is consistent with the fact that during days 2 ± 5 in the presence of TPA the cells grew more rapidly than the untreated cells (data not shown). Previous studies and our own studies ( Figure 1 ) indicated that HC11 cells express at least four isoforms of PKC, a, d, e, and z, amongst which PKCz is the only one that is not responsive to activation by TPA. It is known that the treatment of cells with TPA initially leads to activation and translocation of responsive PKC isoforms, and that this is often followed by subsequent proteolytic downregulation of these proteins due to ubiquitin-mediated degradation and to the sensitivity of the conformation of activated PKCs to cellular proteases (Kishimoto et al., 1989; Lu et al., 1998; Lee et al., 1996; Savart et al., 1992) . After treating HC11 cells with 100 ng/ml TPA, Western blot analysis of solubilized total cell lysates showed no alterations in the protein levels of PKCz, but there was a marked loss of PKCd and PKCe within 1 h after the addition of TPA (Figure 1 ). In contrast, loss of PKCa was not seen at 1 or 6 h, but was apparent at 24 h (Figure 1 ). Since PKCd and PKCe are downregulated very rapidly, it seemed unlikely that activation of these enzymes mediated the cell cycle arrest seen at 6 h after the addition of TPA. On the other hand these data suggested that the abovedescribed TPA-induced transient growth inhibition and delay in G1 to S progression might be mediated by activation of PKCa, and that the subsequent downregulation of PKCa (after 6 h) relieved this inhibition.
Overexpression of PKCa and PKCb 1 in HC11 cells and eects on PKC translocation and cell morphology To further explore the above phenomena (transient cell cycle arrest and downregulation of PKCa) we ®rst derived a subclone of the HC11 cell line (tTA3) that carries the tetracycline-VP16 transactivator that can be used to overexpress any ectopic protein in an inducible manner, utilizing the tetracycline-responsive system developed by Gossen and Bujard (1992) . This subclone was then used to develop derivatives that conditionally overexpress PKCa. Since our laboratory had previously studied in detail PKCb1 (Choi et al., 1990; Goldstein et al., 1995; Housey et al., 1988; Hsiao et al., 1989) it was also of interest to develop derivatives that conditionally over-express this closely related isoform of PKC to see if it would have eects similar to those of PKCa. Pools and individual clones of cells that inducibly overexpress either PKCa (HC11-PKCa) or PKCb 1 (HC11-PKCb 1 ) and vector control cells (HC11-UHD) were obtained from the tTA3 cell line and further analysed. Western blot analysis of the HC11-PKCa cells indicated that these cells expressed about a threefold higher level of PKCa when grown in the absence rather than the presence of tetracycline (tet) (Figure 2a ). Two clones of the HC11-PKCb 1 cells displayed a marked induction of PKCb 1 when grown in the absence of tet (Figure 2b ). When grown in the presence of tet, expression of either the ectopic PKCa or PKCb 1 were largely, although not completely, repressed in the respective clones (Figure 2a,b) . Studies on the vector control cell line HC11-UHD (Figure 2a ). When the HC11-PKCb 1 cells were grown in the absence of tet, the ectopic expression of PKCb 1 was also maintained at a relatively high level in the presence of TPA (data not shown). Ectopic expression of either PKCa or PKCb 1 did not alter the endogenous levels of PKCe, PKCd or PKCz (data not shown).
Immunohistochemical staining with antibodies speci®c for PKCa indicated that in the parental cells, in the absence of treatment with TPA, PKCa was mainly localized in the cytoplasm, although there was some weak perinuclear and nuclear staining (Figure 3) . Treatment with 100 ng/ml TPA induced a striking translocation of PKCa into the nucleus. This occurred within 30 min and was maintained for at least 6 h. Similar results were obtained with the HC11-PKCa cells grown in the absence of tet but the staining for PKCa was more intense and the nuclear translocation following treatment with TPA was maintained for at least 2 days (data not shown). Studies with the HC11-PKCb 1 cells indicated that PKCb 1 was mainly localized in the cytoplasm and did not undergo translocation to the nucleus after treatment with TPA (data not shown). To con®rm these cellular localization results we performed biochemical fractionation of cell extracts into the cytoplasmic (including the associated membranes) and nuclear compartments. Western blot analyses of solubilized proteins from these fractions were then performed using antibodies speci®c for either PKCa or PKCb 1 (Figure 4a ,b). In the HC11-PKCa cells grown in the absence of tet, PKCa was found in both the cytoplasmic and nuclear fractions, but within 30 min after treating the cells with TPA it was redistributed almost entirely to the nuclear fraction ( Figure 4a ). When the HC11-PKCb 1 cells were grown in the absence of tet much more of the PKCb 1 protein was in the cytoplasmic fraction and there was no evidence of translocation of PKCb 1 to the nuclear fraction, or to other cellular compartments, after treatment with TPA ( Figure 4b ).
Light microscopy studies indicated that when the parental HC11 or HC11-UHD cells were treated with 100 ng/ml TPA, they displayed a`¯at' cell morphology within 15 ± 30 min which lasted a few hours before the cells resumed their normal epithelioid appearance, despite the continued presence of TPA (data not shown). When the HC11-PKCa or HC11-PKCb 1 cells were treated with TPA, in the absence of tet, they also rapidly developed a¯at cell morphology, but after 5 days they still maintained this abnormal appearance. This`¯at' cell morphology was characterized by an enlarged cytoplasmic area and a¯atter and rounder, less epithelioid appearance. Furthermore chronic (416 h) treatment with TPA often induced the formation of perinuclear or cytoplasmic vacuoles in the PKCa or PKCb 1 overexpressor cells, but not in the parental HC11 or HC11-UHD control cells. Similar vacuoles were noted by Manni et al. (1996) and Ways Cultures were grown in either the presence (+) or absence (7) of 2 mg/ml tetracycline and, where indicated, were treated with TPA (100 ng/ml) for 24 h prior to harvest. (b) Protein lysates from exponentially growing cultures of the indicated cell lines were used for Western blot analysis with an antibody speci®c for PKCb 1 . Cultures were grown in either the presence (+) or absence (7) of 2 mg/ml tetracycline Figure 3 TPA induces the nuclear translocation of PKCa. Exponentially growing HC11 cells were untreated (7) or treated (+) with TPA (100 ng/ml) for 1 h and were then ®xed and immunohistochemically stained with an antibody speci®c for PKCa PKC mediated growth inhibition and p21 cip1 induction ED Slosberg et al et al. (1995) in derivatives of MCF-7 cells that overexpress PKCa, and were hypothesized to be secondary lysosomes. These vacuoles did not stain with Oil Red O (data not shown), suggesting that we were observing an expansion of the endoplasmic reticulum previously seen in TPA treated breast cancer cells (Kiley et al., 1996) , rather than lipid formation.
Eects on growth and cell cycle progression
To determine the eects of overexpression of PKCa or PKCb 1 on growth we carried out a series of growth curve studies using monolayer cultures. The results with respect to the exponential phase doubling times of the vector control and overexpressing cells are summarized in Figure 5 . When the cells were seeded at a low density and grown in standard growth media (GM; RPMI+10% FBS) in the absence of TPA, the exponential population doubling time of the HC11-UHD control cells, and parental HC11 cells (data not shown), was about 16 h, in the absence or presence of tet. This value was similar when the PKCa or PKCb 1 overexpressing cells were grown in the presence of tet. However, in the absence of tet, when the ectopic expression of PKCa or PKCb 1 were induced (Figure 2 ), the exponential doubling times increased to about 20 h, demonstrating that increased expression of either form of PKC caused growth inhibition. When similar growth curves were done in the presence of 100 ng/ ml TPA there was a slight increase in the doubling time of the UHD cells, to about 19 h, both in the absence and presence of tet ( Figure 5 ). However when the ectopic expression of PKCa or PKCb 1 were induced by removing tet and the cells were exposed to TPA, there was a marked increase in the exponential doubling time, to about 26 ± 28 h ( Figure 5 ). Therefore, activation of the overexpressed PKCa or PKCb 1 by TPA resulted in further growth inhibition. The saturation densities of HC11 cells were not significantly aected by the ectopic overexpression of PKCa or PKCb 1 (data not shown).
We also employed a second method to demonstrate the growth inhibitory eects of these isoforms of PKC. The HC11 tTA3 cell line (which carries the tet activator) was transfected with the expression plasmids UHD-PKCa or UHD-PKCb 1 , or only the vector control plasmid UHD. The cells were then grown for 2 weeks in medium containing G418, to select for transfectants, in the absence or presence of tet, and the colonies were then ®xed, stained and counted. Growth in the absence of tet, which induces the expression of PKCa or PKCb 1 , caused a marked inhibition in the number and in the size of the colonies obtained. The numbers of colonies obtained with the HC11-UHD control cells were 113 in the plus tet condition and 102 in the minus tet condition. The respective values for the HC11-PKCa cells were 125 and 44 and for the HC11-PKCb 1 cells were 102 and 51. Therefore, in this colony forming assay system overexpression of PKCa or PKCb 1 also markedly inhibited growth. 
H]thymidine incorporation assays
We also examined the eects of these PKCs on cell cycle progression from the G0 into the S phase. The kinetics of S phase entry in synchronized cultures was assayed by measuring DNA synthesis in a [ 3 H]thymidine pulse labeling experiment ( Figure 6 ). HC11 cells can be eciently synchronized in G0/G1 by serum-starvation for 36 h (data not shown and Sgambato et al., 1996) . After re-stimulation with 10% FBS, the HC11-UHD cells re-entered the cell cycle and progressed into S phase at about 12 ± 15 h, as measured by PKCa, but not PKCb 1 , is present in the nuclear fraction after treatment with TPA. Exponentially growing cultures of HC11-PKCa or HC11-PKCb 1 were untreated (7) or treated (TPA) with TPA (100 ng/ml) for 30 min, biochemically separated into nuclear or plasma membrane/cytosolic fractions and the respective proteins examined by Western blot analysis with antibodies speci®c for PKCa (a) or PKCb 1 (b). The decreased protein levels of PKCb 1 after TPA treatment is due to proteolytic degradation during the cell fractionation (data not shown) Figure 5 Increased PKC activity results in decreased growth in the HC11 mammary epithelial cell line. The initial exponential phase doubling times of the indicated cell lines when grown in standard medium in the presence (+Tet) or absence (7 Tet) of 2 mg/ml tetracycline. In the right panel growth analysis was performed in the continued presence of TPA (100 ng/ml). S.d. are indicated by the thin bars upper panel). In the absence of TPA, the HC11 cells that overexpressed either PKCa or PKCb 1 did not show any signi®cant delay in S phase entry when compared to the vector control cells (data not shown). To see if activation of the ectopic PKCs by TPA resulted in altered S phase entry, serum-starved HC11-UHD, HC11-PKCa and HC11-PKCb 1 cells, grown in the absence of tet, were treated with 100 ng/ml TPA at dierent time points after re-stimulation with 10% FBS, and the levels of DNA synthesis were assayed by measuring [ 3 H]thymidine incorporation at 20 h after the addition of FBS, since this time point represented the approximate peak of S phase. This protocol also allowed us to determine at which point in the transition from G0 to S phase PKC activation had its greatest eect. In the HC11-UHD control cells the addition of TPA from time 0 ± 20, 12 ± 20 or 16 ± 20 h produced a 16.7% inhibition of [ 
Eects on p21 cip1 induction
To explore how treatment with TPA impedes the G1 and S progression in HC11 cells, we examined cellular levels of the protein p21 cip1 since p21 cip1 inhibits passage through these phases of the cell cycle. This protein can bind to and inhibit the function of several cyclin-cyclindependent kinases (CDKs) and it also can bind to Upper panel: HC11 cells were synchronized by serum starvation and refed with media containing serum to induce re-entry into the cell cycle. At dierent times after the addition of serum the amount of DNA synthesis was assayed by measuring the levels of acid-insoluble radioactivity following a 1 h incubation with 1 mCi/ ml [ 3 H]thymidine. The peak of S phase was at 20 h after serum addition. The bars at the top indicate the times during this progression from G0 to S phase when TPA was added, as described in the experiment below. Lower panel: The indicated cell lines were synchronized and then stimulated to re-enter the cell cycle, as described above. At 19 h after re-stimulation with serum the amount of DNA synthesis was assayed (as above). Samples were untreated or treated with TPA (100 ng/ml) for dierent lengths of time (as shown in the upper panel) prior to the addition of [ 3 H]thymidine. All assays were done in triplicate. S.d. are represented by the thin bars cip1 cDNA probe. TPA was used at 100 ng/ml. Cycloheximide (CHX; 10 mg/ml) and actinomycin D (AcD; 5 mg/ ml) were added to the culture 20 min before the addition of TPA, as indicated. The superinduction of p21 cip1 mRNA following coincubation with CHX plus TPA was con®rmed by densitometry PCNA, a protein essential for DNA synthesis, thereby impeding progression through the cell cycle (for review see Hunter and Pines, 1994; Sherr and Roberts, 1995; Weinstein and Zhou, 1996) . Exponentially dividing cultures of the parental HC11 cells were treated with 100 ng/ml TPA for dierent lengths of time and extracts were analysed in Western blots with antibodies speci®c for p21 cip1 . We found a marked increase in the levels of this protein at 6 h after TPA treatment (Figure 7a ) with a return to the basal levels at 24 h. These results are consistent with the transient cell cycle inhibition in G1 previously observed in HC11 cells (Table 1 ). The p53 protein often plays a role in the induction of p21 cip1 , but since the HC11 cell line is p53 de®cient (Merlo et al., 1994) , this induction by TPA apparently occurs via a p53-independent pathway.
Northern blot analysis indicated a signi®cant increase in p21 cip1 mRNA within 2 h after the addition of TPA to HC11 cells. This level was very high at 6 h and then returned to the basal level by 24 h ( Figure  7b ). Pretreatment of the cells with the RNA synthesis inhibitor actinomycin D completely abrogated the induction of p21 cip1 mRNA by TPA (Figure 7b) , suggesting that the increase in p21 cip1 mRNA was not due to increased mRNA stability, but instead to induction of transcription of the p21 cip1 gene. We found that treatment with cycloheximide caused some induction of p21 cip1 mRNA, which is consistent with previous evidence that cycloheximide can induce the transcription of other cellular genes (Vilcek et al., 1976) . Cells pretreated with cycloheximide before the addition of TPA displayed a superinduction of p21 cip1 mRNA (Figure 7b ). These ®ndings provide evidence that ongoing protein synthesis is not necessary for the induction of p21 cip1 mRNA, and suggest that this induction is a direct eect of a PKC signaling pathway.
When we examined exponentially growing cells in the absence of TPA, the p21 cip1 protein was not detected in either the control, PKCa or PKCb 1 overexpressing cells (Figure 8 ). However after 6 h of treating these cells with 100 ng/ml TPA the p21 cip1 protein was induced in all three cell types, but the level was considerably higher in both the PKCa and PKCb 1 overexpressor cells, when compared to the vector control cells (Figure 8 ). TPA treatment also induced a higher level of p21 cip1 mRNA in the PKCb 1 overexpressor cells than in the vector control cells (data not shown).
Discussion
The present study provides evidence that PKCa plays a critical role in growth control and cell cycle regulation in HC11 mammary epithelial cells, and that this isoform can also modulate the expression of cellular levels of the CDK-inhibitor p21 cip1 . Evidence supporting a role for PKC in cell cycle regulation has also been obtained in several previous studies (Livneh and Fishman, 1997; Sasaguri et al., 1993; Thompson and Fields, 1996) . Thus, studies in vascular endothelial cells (Fukumoto et al., 1997; Zhou et al., 1993) , melanoma cells (Coppock et al., 1995) and hematopoietic cells (Tiefenbrun and Kimchi, 1991) have shown altered cell cycle progression and altered levels of various cyclins, CDKs, CDIs and CDK-kinase activities in response to PKC activation (for review see Livneh and Fishman, 1997; Thompson and Fields, 1996) . Studies in vascular smooth muscle cells provide evidence that PKCa and PKCe play a role in mediating TPA induced inhibition of the G1 to S phase transition (Sasaguri et al., 1993) . A recent study of IEC-18 cells found that TPA induced a transient arrest in the G1 phase and that this was associated with induction of p21 cip1 and p27
kip1
, and hypophosphorylation of pRb (Frey et al., 1997) . Studies on the dierential down-regulation of individual PKC isoforms suggested that PKCa, in particular, was sucient to mediate this cell cycle arrest in this system (Frey et al., 1997) . These ®ndings are consistent with the present results in HC11 mammary epithelial cells.
We found that when HC11 cells were treated with TPA, both the endogenous and exogenous PKCa translocated from the cytosol into the nucleus (Figures 3 and 4) . There have been numerous reports of the translocation of PKC isoforms into the nucleus, usually in response to treatment with mitogens (ie., TPA, IGF, PDGF) (reviewed in Buchner, 1995; Leach and Raben, 1993; Olson et al., 1993) . Furthermore, the nucleus maintains distinct Ca 2+ , DAG and phospholipid cycles that could play a role in regulating nuclear PKC activity and several nuclear substrates for PKC have been identi®ed (Divecha et al., 1993; Livneh, 1994) . The speci®c physiologic substrates of nuclear PKCa in HC11 cells and in mammary epithelial cells, in general, remain to be identi®ed. It is of interest that, when activated, PKCa underwent translocation to the nucleus, but this was not the case with the ectopically expressed PKCb 1 (Figure 3 and 4 and data not shown). These two proteins show an 82% overall sequence identity (by BLAST analysis (Altschul et al., 1990) ), but diverge to a greater extent in the variable regions (V1 ± V5) that are dispersed throughout the protein.
The mechanism by which PKCa is targeted to the nucleus is not clear, but it may involve speci®c nuclear proteins that can recognize and bind PKCa (MochlyRosen, 1995) . Several PKC-binding proteins have been identi®ed (RACKs, PICKs, F52, 35H) of which at least one is localized to the nucleus (PICK1) (Staudinger et al., 1995) . Mutagenesis studies of PKCa have revealed several potential nuclear localization sequences (NLS), one near the V3 hinge region and one in the C-terminal V5 region (Eldar et al., 1992; James and Olson, 1992 ). Furthermore we have previously shown that when ectopically expressed in R6 ®broblasts a mutant PKCa with a point mutation in the V3 hinge region (D294G), found in human pituitary and thyroid tumors, Figure 8 p21 cip1 protein levels are increased in HC11 cells that overexpress PKCa or PKCb 1 . Protein lysates were prepared from exponentially growing HC11 cells that overexpress PKCa (pBabePKCa), PKCb 1 (pBabe-PKCb 1 ) or vector control (pBabe-). The cells were either untreated (7) or treated with TPA for 6 h. Western blot analysis was then performed using an antibody speci®c for p21 cip1 translocated to the perinuclear region and the nucleus when the cells were treated with TPA, in contrast to the wild-type PKCa which did not translocate to the nucleus in this cell line (Alvaro, 1993; Alvaro et al., 1997) . These ®ndings suggest that the residues that determine nuclear localization reside in the less conserved (variable) regions of PKCa. Furthermore the cytoskeleton may also play a role in this process, since TPA-induced translocation of PKCa to the nucleus of NIH3T3 cells was blocked by cytoskeleton disrupting agents, whereas the nuclear accumulation of a canonical nuclear localization signal reporter protein was not (Schmalz et al., 1996) . It is of interest that although PKCa and b 1 can reside in dierent subcellular locations after TPA treatment, we found that their eects on growth and p21 cip1 induction were similar. This suggests that these two isoforms of PKC might act through dierent signaling pathways, or at dierent points in the same pathway, to inhibit growth.
We propose the following model to explain the results of the present studies. Shortly after exposing HC11 cells to TPA, PKCa becomes activated and is translocated to the nucleus where it directly leads to increased transcription of p21 cip1 . This presumably involves the direct or indirect phosphorylation and activation of a transcription factor which binds to and activates the p21 cip1 promoter. The resulting increased level of p21 cip1 protein retards cell cycle progression by binding to and inhibiting the kinase activity of G1 cyclin-CDK complexes (cyclinD-CDK4, cyclinE-CDK2), thereby causing an inhibition of G1 progression. Several hours after the addition of TPA, PKCa is down regulated due to the sensitivity of its active conformation to cellular proteases. The absence of PKCa relieves the induction of p21 cip1 , and the lower levels of p21 cip1 allow for re-activation of G1 cyclin-CDK complexes, thus enhancing progression through the cell cycle. In our PKCa overexpressor derivatives, TPA-induced down-regulation is impaired due to the high levels of PKCa. Thus p21 cip1 levels can remain high and inhibit growth to a greater extent than in the parental HC11 cells. Apparently, PKCb 1 can exert similar eects although in this case the induction of p21 cip1 does not require translocation of this isoform of PKC to the nucleus. The relevance of this model to human mammary epithelial cells and to mammary carcinogenesis remains to be determined.
Materials and methods
Plasmid construction
To create the pUHD-PKCa plasmid pBabe-PKCa (Alvaro et al., 1997) was cut with EcoRI, and the human cDNA encoding PKCa was gel-puri®ed using the Qiaex kit (Qiagen, Chatsworth, CA, USA) and ligated into the EcoRI site of the pUHD 10-3 vector (Gossen and Bujard, 1992) . To create the pUHD-PKCb 1 plasmid the RP58 plasmid (Housey et al., 1988) was digested with HindIII and NotI, and the rat cDNA encoding PKCb 1 was gel-puri®ed and then ligated into the pMT vector digested with HindIII and NotI, creating pMTPKCb 1 . pMT-PKCb 1 was then digested with BamHI, and the fragment containing the PKCb 1 cDNA gel-puri®ed and ligated into the BamHI site of pUHD 10-3. The pBabe vector and pBabe-PKCa plasmids were previously described (Alvaro et al., 1997) . To create pBabe-PKCb 1 the RP58 plasmid was digested with BamHI, and the rat cDNA encoding PKCb 1 was gel-puri®ed and ligated into the pBabe vector digested with BamHI, creating pBabe-PKCb 1 .
Tissue culture HC11 cells were grown in RPM1 1640 medium plus 10% fetal bovine serum (GM). To create a tetracycline (tet) responsive derivative, parental HC11 cells were co-transfected with pBabe (containing a puromycin r cassette) and a tenfold excess of pUHD 15-1 (tetRepressor-VP16 expression plasmid), and selected for 2 weeks with 1 mg/ml puromycin. Puromycin-resistant clones were isolated and tested for tetracycline-inducible expression of the pUHC13-3 luciferase construct, in a transient transfection assay (Gossen and Bujard, 1992) . HC11 Clone tTA3 showed *100-fold higher luciferase activity in the absence of tet compared to the presence of tet, and was, therefore, chosen for further studies. This tet responsive derivative was maintained in the presence of 2 ± 4 mg/ml tetracycline (tet) and 1 mg/ml puromycin (except during speci®c experiments). HC11 tTA3 cells were then co-transfected with pMT (containing a G418 r cassette) and a tenfold excess of either pUHD-PKCa or pUHDPKCb 1 . Two days later the cells were refed with GM+2 mg/ ml tet+1 mg/ml puromycin+200 mg/ml G418. After 2 ± 3 weeks of selection individual clones were isolated or pooled for future studies. These derivatives (HC11-PKCa and HC11-PKCb 1 ) were maintained in GM+2 mg/ml tet+1 mg/ml puromycin+100 mg/ml G418, except during speci®c experiments. After extensive growth in culture, several pools and clones lost the ability to overexpress PKCa or PKCb 1 . For this reason early passages were used and the overexpression of the appropriate PKC isoform was con®rmed in each experiment. At the start of all experiments, tet was removed from the cells with two washes with 3 ml of PBS before being refed. TPA (12-O-tetradecanoyl 13-phorbol acetate; obtained from Sigma Chemical Co. or from LC Laboratories) was dissolved in DMSO at a concentration of 1 mg/ml and used at a ®nal concentration of 100 ng/ml. Transfections were performed using the Lipofectin reagent (Gibco ± BRL; MD, USA) according to the manufacturer's instructions.
Growth curves
Cells were plated at a density of 5610 3 cells per well in 6-well (35 mm diameter) plates in GM+2 mg/ml tet. The following day (day 0) the cells were washed twice with PBS and refed with GM+2 mg/ml tet+100 ng/ml TPA. The number of cells were determined every other day until con¯uence using a Coulter Counter. The doubling times were calculated from the initial exponential phase of growth and the data presented are the mean of three independent experiments.
Colony forming assays
2.5610
5 HC11 tTA3 cells were transfected (using lipofectin) with 1 mg pMT (G418 r ) plus 5 mg of the indicated plasmid, in the presence of tet. After recovery for 2 days in GM plus tet each plate was split onto two plates and grown in GM+200 mg/ml G418, in either the presence or absence of tet (2 mg/ml). After 2 weeks of growth the plates were ®xed with paraformaldehyde, stained with 5% Giemsa v/v, photographed, and the number of colonies counted. H-thymidine (1 mCi/ml; Amersham, Arlington Heights, IL, USA) and then washed with ice-cold PBS and extracted twice with cold 10% trichloroacetic acid (TCA) for 15 min on ice. After solubilization in 0.5 N NaOH for 30 min at 378C, the TCA-insoluble radioactivity was determined by liquid scintillation counting.
Cytostaining and FACS analysis
5610
5 parental HC11 cells were plated in GM and the following day they were refed with GM+100 ng/ml TPA. At the indicated times the cells were harvested for FACS as described previously (Sgambato et al., 1996) . The numbers in Table 1 are the mean of four independent experiments.
Immunohistochemistry 10 4 cells were plated/well on polylysine-D treated chamber slides (Nalge Nunc, Rochester, NY, USA) and allowed to grow for 1 ± 2 days. After treatment with TPA (100 ng/ml) for various times the slides were washed three times in PBS, ®xed in formaldehyde and prepared for immunohistochemistry as described elsewhere (Alvaro et al., 1997) . The antibodies used were 5 mg/ml anti-PKC a (anity puri®ed preparation from Gibco ± BRL) and a 1 : 1000 dilution of FITC-a-rabbit IgG (BioSource). Photographs were taken with a¯uorescent microscope at 4006magni®cation.
Western blot analyses
Prior to protein extraction the cells were grown in the presence or absence of tet for 48 h (unless otherwise noted). Cultures were then washed with PBS, and collected in 300 ± 500 ml of RIPA buer. After a brief sonication, the lysates were incubated on ice for 10 ± 15 min before clarifying by centrifugation, and stored at 7208C. Equal amounts of total protein were resolved by SDS ± PAGE transferred onto Immobilon-P membranes (Millipore; Bedford, MA, USA) and immunoblotted with speci®c antibodies, as previously described (Sgambato et al., 1996) .
Nuclear fractionation
The nuclear fractionation protocol was largely derived from previous protocols (Leach et al., 1989 (Leach et al., , 1992 Leach and Raben, 1993) . Exponentially growing cells were fed with GM+100 ng/ml TPA. After 30 min the cells were washed twice with ice-cold PBS. The cells were scraped into an Eppendorf tube using a rubber policeman in 0.5 ml of nuclei buer (NB ± 10 mM Tris, pH 7.5; 10 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% Triton X-100; and protease inhibitors). After incubation on ice for 10 min, the cells were homogenized ten times with a Dounce Pestle A, and then spun for 5 min at 48C and 500 g. The supernatant fraction was transferred to a new tube, sonicated, and saved as the Cytosolic/Plasma Membrane Fraction. The 500 g pellet was resuspended in 300 ml NB and layered over 300 ml NB+45% sucrose in an Eppendorf tube. This was then spun at 1660 g at 48C for 30 min. The pellet was resuspended in 500 ml NB+10% sucrose+1 mM MgCl 2 , homogenized seven times with a Dounce Pestle A and spun at 500 g at 48C for 5 min.
The pellet was resuspended in buer B (25 mM Tris, pH 7.5; 2 mM EDTA; 0.5 mM EGTA; 5 mM b-mercaptoethanol) and sonicated to lyse the nuclei. Equal protein amounts were then run on a 8% PAGE and Western blotted (see above). All buers contained the protease inhibitors leupeptin (5 mg/ml), aprotinin (5 mg/ml), and PMSF (1 mM). Despite the presence of these protease inhibitors PKCb 1 from TPA treated samples was degraded during this procedure as revealed by Western blots. The reason for the selective loss of PKCb 1 , and not PKCa, is not clear.
Northern blot analyses
RNA was prepared using the single-step method, as previously described (Chomczynski and Sacchi, 1987; Choi et al., 1990) . Exponentially growing HC11 cells were treated with TPA (100 ng/ml) for varying amounts of time before harvesting for RNA extraction. Cycloheximide (10 mg/ml) and actinomycin D (5 mg/ml) were added to the culture media 20 min before the TPA treatment. Northern blotting was performed as previously described (Sgambato et al., 1996) . The blotted membranes were hybridized with 32 P-labeled mouse p21 cip1 or GAPDH cDNAs overnight. The membranes were washed with 26SSC containing 1% SDS for 20 min at room temperature and twice for 20 min at 658C (for GAPDH), and then washed with 0.26SSC containing 1% SDS for 5 min (for p21 cip1 ), before exposure to ®lm. The GAPDH probe was a 1.3 Kb rat PstI cDNA fragment. The p21 cip1 probe was a mouse EcoRI cDNA fragment. a-
32
PdCTP-labeled cDNA probes were made by random primer labeling using the Multiprime DNA labeling system (Amersham Life Sciences) with 25 ± 50 ng of a puri®ed cDNA fragment.
Materials
Unless otherwise noted all supplies were obtained from Sigma Chemical (St. Louis, MO, USA). Antibodies used were mouse a-PKCb 1 (MC-2a from Seikagaku Corp, Tokyo, Japan) and a generous gift of rabbit a-PKCb 1 from Susan Jaken; rabbit a-PKCa (anity puri®ed) from Gibco ± BRL; mouse a-PKCd, a-PKCe and a-PKCz from Transduction Laboratories (Lexington, KY, USA); rabbit a-p21 cip1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); and hrpconjugated goat anti-rabbit or goat anti-mouse (Amersham, Arlington Heights, IL, USA).
